Proposal to fund another brand of methylphenidate for ADHD
- admin82291
- 3 hours ago
- 1 min read
Kia ora,Pharmac is seeking feedback on a proposal to fund another brand of methylphenidate - Rubifen LA - to help ease ongoing supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD).
If approved, this brand would be funded from 1 July 2026.
We welcome your feedback. Consultation is open until 5 pm, Thursday 4 December 2025. Please send your feedback to consult@pharmac.govt.nz or use the online form linked in the consultation.
Ngā mihi,
Ashleigh Kleinsman (she/her) | Therapeutic Group Manager
Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 | www.pharmac.govt.nz